Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.

"Declarations Ethics approval and consent to participate: No specific consent was required since this was a retrospective analysis of anonymized patient data from hospital records.Consent for publication: No specific consent for publication was required since this was a retrospective analysis of anonymized patient data from hospital records.Author contributions:Mattea Reinisch: Conceptualization; Data curation; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing – review & editing.Simona Bruzas: Conceptualization; Data curation; Investigation; Methodology; Visualization; Writing – review & editing.Jennifer Spoenlein: Data curation; Investigation; Writing – review & editing.Satyendra Shenoy: Formal analysis; Methodology; Visualization; Writing – original draft; Writing – review & editing.Alexander Traut: Data curation; Formal analysis; Software; Validation; Writing – review & editing.Hakima Harrach: Data curation; Investigation; Writing – review & editing.Ouafaa Chiari: Data curation; Investigation; Writing – review & editing.Efsthatia Cremer: Data curation; Investigation; Writing – review & editing.Beyhan Ataseven: Data curation; Investigation; Visualization; Writing – review & editing.Lars Gubelt: Data curation; Investigation; Writing – review & editing.Sherko Kuemmel: Conceptualization; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Writing – review & editing.Funding: The authors received no financial support for the research, authorship, and/or publication of this article.Competing interests: MR reports honoraria from Pfizer, Novartis, Lilly, Roche Pharma AG, AstraZeneca, Daiichi Sankyo, SOMATEX, Seagen, Pfizer and Gilead; personal fees for consulting or advisory services from Roche Pharma AG, Daiichi Sankyo, Lilly, Novartis, Seagen, Pfizer, Somatex, Gilead, AstraZeneca and MSD Oncology outside the submitted work. SS reports professional fees from Sanofi, Abbvie, Bayer, Cantargia, Celgene, Ferring, Nestle, Servier, Tiburio and Zentiva on unrelated freelance projects. HH reports travel expenses from Pfizer and Teva. OC reports travel expenses from Pfizer. BA reports advisory fees from Roche, Amgen and Tesaro; lecture honoraria from Roche, Tesaro, Celgene, Clovis and AstraZeneca and travel/accommodation expenses from Roche, Tesaro and PharmaMar. LG reports consultation fees from Daichii Sankyo, Otsuka Pharma, AstraZeneca, MSD, Roche Pharma AG, Pfizer and B. Braun Melsungen. SK reports personal fees from Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, pfm medical, Pfizer, MSD Oncology, Lilly, Sonoscape, Gilead Sciences, Seagen and Agendia for consulting or advisory services; travel and accommodation expenses from Roche, Daiichi Sankyo and Sonoscape outside the submitted work. SK is also co-director of the WSG Study group.Availability of data and materials: Data supporting the findings of this study are available in Tables 1 and 2 and Figures 1 to 3. Drs. Reinisch, Bruzas and Spoenlein had full access to patient data. Dr. Reinisch and Mr. Traut took responsibility for the integrity of the data and data analysis. Competing interests: MR reports honoraria from Pfizer, Novartis, Lilly, Roche Pharma AG, AstraZeneca, Daiichi Sankyo, SOMATEX, Seagen, Pfizer and Gilead; personal fees for consulting or advisory services from Roche Pharma AG, Daiichi Sankyo, Lilly, Novartis, Seagen, Pfizer, Somatex, Gilead, AstraZeneca and MSD Oncology outside the submitted work. SS reports professional fees from Sanofi, Abbvie, Bayer, Cantargia, Celgene, Ferring, Nestle, Servier, Tiburio and Zentiva on unrelated freelance projects. HH reports travel expenses from Pfizer and Teva. OC reports travel expenses from Pfizer. BA reports advisory fees from Roche, Amgen and Tesaro; lecture honoraria from Roche, Tesaro, Celgene, Clovis and AstraZeneca and travel/accommodation expenses from Roche, Tesaro and PharmaMar. LG reports consultation fees from Daichii Sankyo, Otsuka Pharma, AstraZeneca, MSD, Roche Pharma AG, Pfizer and B. Braun Melsungen. SK reports personal fees from Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, pfm medical, Pfizer, MSD Oncology, Lilly, Sonoscape, Gilead Sciences, Seagen and Agendia for consulting or advisory services; travel and accommodation expenses from Roche, Daiichi Sankyo and Sonoscape outside the submitted work. SK is also co-director of the WSG Study group."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."